Tumour-associated macrophages (TAMs)
Tumour-associated macrophages are immune cells that should eat cancer cells but are re-educated by the tumour to protect it instead. They are often the most abundant immune cell in a tumour.
Mostly M2-like, immunosuppressive, pro-angiogenic; recruited by CSF1 and CCL2; express PD-L1, SIRPα, TREM2. Targets: CSF1R (pexidartinib approved in TGCT; broadly disappointing in cancer), CD47/SIRPα (magrolimab failed), TREM2, CD40 agonists. Depleting M2 TAMs is also the rationale of the MERTK ADC RGX-019-MMAE.
Pages like this
not linked directly; found by shared links- TermMyeloid-derived suppressor cells (MDSCs)
Shares Macrophage, Nutrient competition & metabolic immunosuppression, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Tumour microenvironment (TME).
- PersonIrving L. Weissman
Shares Magrolimab, CD47.
- IdeaCan MYC be drugged directly, and will patients tolerate it?
- IdeaBispecific antibodies that engage macrophages instead of T cells
Shares Magrolimab, CD47.
- TermImmune exclusion
Shares Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Tumour microenvironment (TME).
- TermImmune system
Shares Macrophage, Tumour microenvironment (TME).
- TargetCSF1R
Shares Nutrient competition & metabolic immunosuppression, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals.
- PathwayJAK–STAT signalling
Shares Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, PD-L1.